性别特异性微轴流泵使用与梗死相关心源性休克结局:DanGer Shock 试验
DanGer Shock 试验的预设性别特异性二次分析纳入 355 例 STEMI 合并心源性休克患者(女性 74 例,男性 281 例),比较微轴流泵(mAFP)与标准治疗的 180 天全因死亡率。女性年龄更大、症状至随机化时间更长,180 天死亡率显著高于男性(64.9% vs 48.8%,P=0.015);治疗分配与性别交互作用不显著(P=0.18),女性 HR 1.01(95%CI 0.58-1.79),男性 HR 0.66(95%CI 0.47-0.93)。
要点
- 女性 STEMI-CS 患者年龄更大且就诊延迟,180 天死亡率显著高于男性。
- mAFP 治疗与性别交互作用不显著,但女性点估计未显示获益。
- ≤76 岁患者中男女均显示 mAFP 获益,交互作用 P=0.92。
核心结论
- 女性 STEMI-CS 患者年龄更大、症状至随机化时间更长,导致死亡率更高,可能解释女性中 mAFP 治疗效应不明显。
- 治疗分配与性别交互作用不显著,年轻患者(无论性别)显示 mAFP 获益。
- 该二次分析未把握度且女性样本少,结果属假设生成性。
研究设计与样本
- 国际、多中心、开放标签、随机对照 DanGer Shock 试验的预设性别特异性二次分析。
- 2013 至 2023 年纳入 355 例 STEMI-CS 患者(排除昏迷心脏骤停),女性 74 例(20.8%),男性 281 例(79.2%)。
- 179 例随机至 mAFP(女性 37 例),176 例随机至标准治疗(女性 37 例)。
- 附设排除患者注册登记 n=495,女性占 25.7%(P=0.10)。
主要发现
- 女性基线年龄显著更大,症状至随机化时间为男性的 2.2 倍。
- 女性 180 天全因死亡率显著高于男性(64.9% vs 48.8%;P=0.015)。
- 性别与治疗分配对 180 天全因死亡率交互作用不显著(P=0.18)。
- 女性 HR 1.01(95%CI 0.58-1.79),男性 HR 0.66(95%CI 0.47-0.93)。
- ≤76 岁患者中,女性(n=41)HR 0.66(95%CI 0.25-1.76),男性(n=233)HR 0.61(95%CI 0.40-0.92),交互作用 P=0.92。
临床怎么用
- 女性 STEMI-CS 患者就诊延迟更明显,应关注性别差异对治疗时机的影响。
- mAFP 在年轻患者(无论性别)中显示获益,可考虑用于该人群。
- 女性中 mAFP 的获益证据有限,临床决策需结合年龄与个体情况。
局限性
- 为二次分析且未把握度,女性样本量少,结果属假设生成性。
- 排除昏迷心脏骤停患者,结论外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The microaxial flow pump (mAFP) has been shown to improve outcomes in selected patients with ST-elevation myocardial infarction (STEMI) and cardiogenic shock (STEMI-CS), but this effect appears to be less evident in women compared with men. OBJECTIVES: The objective of this secondary analysis of the Danish-German Cardiogenic Shock Trial (DanGer Shock) was to determine sex differences in baseline characteristics, in-hospital course, and the effectiveness of mAFP in STEMI-CS. METHODS: This was a prespecified sex-specific secondary analysis of the international, multicenter, open-label, randomized DanGer Shock Trial. The primary outcome was 180-day all-cause mortality, analyzed by sex and randomized treatment assignment. RESULTS: From 2013 to 2023, 355 patients (74 [20.8%] women, 281 [79.2%] men) with STEMI-CS excluding comatose cardiac arrest were enrolled; 179 were randomized to mAFP (37 women) and 176 to standard care (37 women). In an accompanying registry of excluded patients (n = 495), women represented 25.7% (P = 0.10). At baseline, women were significantly older, and time from symptom onset to randomization was 2.2-fold longer in women than in men. Compared with men, women had significantly higher 180-day all-cause mortality (64.9% vs 48.8%; P = 0.015). There was no significant interaction for sex and treatment assignment with respect to 180-day all-cause mortality (P value for interaction = 0.18), yet women (HR: 1.01 [95% CI: 0.58-1.79]) appeared to derive less benefit from mAFP treatment than male patients (HR: 0.66 [95% CI: 0.47-0.93]). This difference was attenuated in patients aged ≤76 years: women (n = 41) HR: 0.66 (95% CI: 0.25-1.76) and men (n = 233) HR: 0.61 (95% CI: 0.40-0.92) (P value for interaction = 0.92). Data from up to 10 years of follow-up support the treatment effect in younger patients, regardless of sex: women HR: 0.45 (95% CI: 0.19-1.09); men HR: 0.57 (95% CI: 0.40-0.82). CONCLUSIONS: In DanGer Shock, women with STEMI-CS were older and presented later after onset of symptoms, resulting in higher mortality rates. This may have led to the apparent reduced treatment effect in women, but interaction between treatment allocation and sex was not significant, and data showing a benefit of mAFP appeared particularly in younger patients, regardless of sex. As this is a secondary, nonpowered analysis that includes few women, its results must be considered hypothesis generating. (Danish Cardiogenic Shock Trial [DanShock]; NCT01633502).
引用
- Mangner, Beske, Hassager, et al. Sex-Specific Microaxial Flow Pump Use and Outcomes in Infarct-Related Cardiogenic Shock in the DanGer Shock Trial. J Am Coll Cardiol. 2025. PMID: 41222528. doi:10.1016/j.jacc.2025.09.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。